Summit4CI Speaker Series

Summit4CI Speaker Series

Summit for Cancer Immunotherapy: Speaker Series
Hosted by BioCanRx, Canada’s Immunotherapy Network

The in-person Summit for Cancer Immunotherapy has been postponed to November 2021 due to the current pandemic. But, in the meantime, BioCanRx is pleased to offer a series of interesting and interactive virtual talks featuring our funded Network Investigators from across the country. Each speaker session will include a plain language overview and wrap up, with an opportunity for questions. Best of all, it’s free to attend.

Register now!

Session Seven:

Novel combination approaches for solid tumours: leveraging checkpoint inhibition and radiation therapy in renal cell carcinoma
Date: Wednesday, April 14, 2021 | 2:30 - 4:00 pm ET

Immune checkpoint blockers, such as Ipilimumab and Nivolumab, have been shown to improve the lifespan of patients with metastatic kidney cancer by unleashing our immune system. However, not every patient benefits from immunotherapy. Understanding the factors that indicate which patients are likely to benefit from treatment, or ways to help immunotherapy work better for more patients, are important, unmet needs. Removal of the primary kidney mass - in disease that has already spread - was shown over 20 years ago to be modestly beneficial for metastatic kidney cancer patients; however, recent studies cast doubt on this benefit in the current immunotherapy era.

Alternatively, highly focused radiation is a convenient, safe method to kill cancer cells that may also enhance our immune response. We hypothesize that combining immunotherapy and highly focused radiation will improve the treatment of kidney cancer for patients who initially present with widely spread disease. To address this hypothesis, we are conducting a randomized phase II clinical trial (CYTOSHRINK) to study the benefits of combining Ipilimumab/Nivolumab and radiation for metastatic kidney cancer patients. Further, our proposed studies interrogating host samples of tumor tissue, blood and stool from immunological and genomic perspectives will provide a deeper understanding of tumor biology at the start and changes during treatment with this novel combination strategy.


Aly-Khan Lalani
Anand Swaminath
Jessica Irvine
Michael Surette
Deborah Maskens
Donna McCarty

Who should attend?

Scientific and health care community including researchers, clinicians and HQP along with patients and caregivers. Note: There will be a plain language overview before the session begins and an opportunity to ask questions after the discussion.

You can find details about our Scientific Programming Committee here

Register now!

You can read more about this research project here:

Questions? Contact [email protected]